Leukemia and Lymphoma Program Clinical Studies

1 - 9 of 9

Phase 1 Study Of Lentivirally Transduced T Cells Engineered To Contain Anti-CD123 In Subjects With Refractory Or Relapsed Acute Myeloid Leukemia

Phase 1 open-label study to estimate the safety, manufacturing feasibility, and efficacy of intravenously administered, lentivirally transduced T cells expressing anti-CD123 in pediatric subjects with relapsed/refractory Acute Myeloid Leukemia (AML). Main study procedures include medical record review, apheresis, CART123 infusion, blood draws, physical exams, imaging, and disease assessments through bone marrows and lumbar punctures. If interested in the study or if you have any questions, please contact 267-426-0762.

AALL1131; A Phase 3 Randomized Trial for HR B-ALL with Dasatinib Arm in Ph-like TKI Sensitive Mutations

The study compares 2 different experimental chemotherapy combinations with the usual chemotherapy combination given during post-Induction therapy. The 3 treatment plans we will be using include: a) therapy containing the usual/standard drugs - Control Arm or, b) therapy containing cyclophosphamide and etoposide- Experimental Arm 1 or, c) therapy containing clofarabine, cyclophosphamide and etoposide – Experimental Arm 2. 

Phase 2 trial of CART19 for Orphan Indications Of Pediatric B Cell Acute Lymphoblastic Leukemia (B-ALL)

This is an open-label, four-cohort, phase 2 study to determine the efficacy of CART19 in pediatric and young adult patients with hypodiploid (Cohort A) or t(17;19) B-ALL (Cohort B), infants with very high risk KMT2A B-ALL (Cohort C), and in patients with central nervous system (CNS) relapse who did not receive cranial radiation (XRT) or bone marrow transplantation (BMT) (Cohort D). Possible procedures include medical record review, apheresis, CART19 infusion, blood draws, physical exams, imaging, and disease assessments through bone marrows and lumbar punctures. If interested in the study or if you have any questions, please contact 267-426-0762.

T2017-002 TACL Ixazomib Study

CHOP and the Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) consortium is conducting a study for children and young adults 21 years old or younger who have relapsed or refractory acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma. This study adds the study drug 'Ixazomib' to standard relapsed ALL chemotherapy drugs. For more information about this study, including specific eligibility criteria, please visit clinicaltrials.gov and search for "NCT03817320" or visit the TACL website at https://tacl.chla.usc.edu/Tacl/#!/Page/3. To hear more about this and other available trails or get any questions answered please contact our Cancer Intake Specialist by phone at 267-426-0762 or email Oncointake@email.chop.edu.

Study of Efficacy and Safety of Tisagenlecleucel in Children and Young Adults with HR B-ALL that is end-consolidation MRD Positive (AALL1721/CASSIOPEIA)

The purpose of this study is to test if the CD19 CAR T cell product tisagenlecleucel (also referred to as CTL019, or Kymriah™) is safe and has beneficial effects in children and young adults who have newly diagnosed high-risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL) that remains MRD-positive after 2 cycles of chemotherapy. The study is enrolling children and young adults between the ages of 1-25 who have received induction and consolidation chemotherapy for HR B-ALL but were still found to have remaining disease (MRD). If you agree to join in this study, you will get one dose of the tisagenlecleucel cells administered by intravenous infusion and be followed for leukemia response. This study also involves blood draws and assessments. Reimbursement for travel may be provided. If you have questions or would like to learn more about the study, please contact the Cancer Immunotherapy Program at (215) 425-7193. The Principal Investigator is Dr. Shannon Maude and the Immunotherapy Nurse Navigator is Brooke Leibfreid, RN.

CD33 CART AML

This phase 1/2 study will determine the safety, feasibility, and efficacy of CD33 CART cells following lymphodepleting chemotherapy in patients with acute myeloid leukemia (AML). Patients who are between ages 1 to 30 years with relapsed or refractory AML will be eligible for this study.

AAML1921; Bosutinib for Chronic Myeloid Leukemia

This study involves taking a study drug called bosutinib. The overall goals of this study are to find the best dose of bosutinib that we can give safely, and to find out what effects, good and/or bad, bosutinib has on children and adolescents with Chronic Myeloid Leukemia (CML). 

Carfilzomib in ALL

CHOP, in collaboration with Onyx Therapeutics, Inc., is conducting a study for children and young adults up to 21 years old, with relapsed or refractory acute lymphoblastic leukemia. This clinical trial is adding the study drug, Carfilzomib, to a standard relapse chemotherapy regimen. For more information about this study, including specific eligibility criteria, please visit clinicaltrials.gov and search for "NCT02303821". To hear more about this and other available trails or get any questions answered please contact our Cancer Intake Specialist by phone at 267-426-0762 or email Oncointake@email.chop.edu.